Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock
Sponsor: Children's Hospital Medical Center, Cincinnati
A PHASE1/PHASE2 clinical study on Septic Shock and Severe Sepsis, this trial is completed. The trial is conducted by Children's Hospital Medical Center, Cincinnati and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital Medical Center, Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .